Traveler’s Diarrhea Market Report and Forecast 2025-2034
Description
The Traveler’s Diarrhea market was valued at USD 1.93 Billion in 2024, driven by the rising prevalence of chronic diseases and the rising incidence of antimicrobial resistance across the 8 major markets. The market is expected to grow at a CAGR of 6.10% during the forecast period of 2025-2034, with the values likely to reach USD 3.49 Billion by 2034.
Traveler’s Diarrhea Market Overview
Traveler's diarrhea is a common gastrointestinal illness that often affects people who visit places with different standards of sanitation and food safety. Consuming contaminated food or water that contains bacteria, parasites (like E. coli), and viruses is the main cause of it. Frequent loose stools, abdominal cramps, nausea, and fever are common symptoms. The illness appears within a week of departure, but it can occur at any time during or after the trip. Most cases are mild and resolve on their own in 2-3 days, but severe cases may require professional medical attention. High-risk areas include countries and parts of the Middle East, Africa, Asia, and Latin America.
In unfamiliar surroundings, travellers frequently encounter pathogens that their immune systems have never encountered before. Visitors are more prone to infections than locals, who may have developed immunity over time. This is particularly true in areas where foodborne or waterborne pathogens, such as Rotavirus or Shigella, are more common but less well-known to tourists from developed countries.
Since dehydration is the main issue, oral rehydration fluids and solutions are essential for management. Examples of preventive measures include avoiding harmful foods and beverages, washing your hands frequently, and using prophylactic drugs or vaccines in specific circumstances. Moreover, travellers frequently believe that bottled water is safe, but in certain countries, tainted water may be sold because of illegal or poorly controlled bottling methods. In some places, tap water may also contain bacteria that cause diarrhea. Reliable access to safe drinking water is a crucial challenge because even seemingly clean water can contain pathogens if local treatment facilities are insufficient.
Traveler’s Diarrhea Market Growth Drivers
Growing Preference for Over the Counter (OTC) Medications to Drive Market Growth
Many tourists would rather use over-the-counter drugs like oral rehydration salts or loperamide (Imodium) to treat their own symptoms. The market for over-the-counter diarrhea remedies has grown because of this trend toward practical, easily accessible solutions. Pharma manufacturing companies are taking good advantage of this by providing products that are easy to use and come in portable, travel-friendly packaging. Hence, propelling the treatment options.
Traveler’s Diarrhea Market Trends
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:
Rising Antimicrobial Resistance to Affect the Market Landscape Significantly
Antimicrobial resistance brought on by the overuse and abuse of antibiotics in some regions of the world has made it more difficult to treat common bacteria. Infections brought on by resistant bacteria may cause travelers to have more severe or protracted symptoms, necessitating more intensive or complex medical treatments. Because of this, traveler's diarrhea is a bigger health risk in areas where resistance is high. For instance, in 2018, Procter & Gamble's new Liquicaps for Pepto Bismol was launched. This product was released as a practical way to treat diarrhea that was perfect for tourists. In contrast to conventional Pepto Bismol, the Liquicaps combat the bacteria that cause diarrhea in addition to treating its symptoms. This launch reflects a growing focus on portable, fast-acting treatments by offering consumers an easy-to-carry solution for digestive issues.
Development of Vaccines and Advances in Probiotic Treatments to Augment Traveler’s Diarrhea Market Demand
Emerging drivers include the creation and marketing of vaccines intended to stop the bacterial causes of traveler's diarrhea, such as those that target E. coli. The market is anticipated to be greatly impacted by these vaccines as they become approved and awareness increases, especially among high-risk travelers. The market is expanding due to the growing popularity of probiotics, which support gut health and may prevent or lessen diarrhea. Probiotics are increasingly being used by travelers as a preventative measure and as a component of a treatment plan, especially as the importance of gut microbiota is getting widely recognized. For Instance, FDA approved Aemcolo, a product of Cosmo Technologies, as a treatment for traveler's diarrhea. In clinical trials, Aemcolo demonstrated efficacy in symptom reduction, providing travelers with relief from E. coli-caused non-complicated diarrhea.
Traveler’s Diarrhea Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Causative Agents:
The Virus Segment Holds a Significant Market Share
The market segmentation by causative agents is divided into bacteria, viruses, and protozoa. Traveler's diarrhea is mainly caused by viruses, especially in places with inadequate sanitation. Norovirus and rotavirus are the most prevalent viral pathogens, and they are transmitted by contaminated food, water, or contact with infected surfaces. The virus inflames the gastrointestinal (GI) tract, resulting in symptoms such as cramps in the abdomen, vomiting, and occasional fever. In comparison to bacterial causes, the viral diarrhea usually resolves on its own within two to three days. Dehydration can happen fast, particularly in susceptible groups like the elderly or children. Since antibiotics are ineffective against viruses, treatment focuses on rehydration and symptom management. Good hygiene and vaccinations (such as the rotavirus vaccine) are effective preventive measures.
Traveler’s Diarrhea Market Analysis by Region
Regionally, Asia Pacific is expected to dominate the market during the forecast period. This can primarily be attributed to rising international travelling and increasing contamination of food and water primarily due to unsanitary living standards and pollution in the region. India and other Asian countries dominated the market in Asia Pacific in 2021 owing to factors such as a high patient pool for major chronic diseases. Additionally, over the course of the forecast period, the presence of major players, early adoption of technology, rising focus on natural and herbal remedies and an increase in research and increasing easy access to travel health clinics are expected to help the regional growth of the market.
Leading Players in the Traveler’s Diarrhea Market
The key features of the market report comprise the patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Bausch Health Company
A multinational pharmaceutical corporation, Bausch Health Company creates, produces, and sells a variety of medical supplies. The company, which was founded in 1959 and has its headquarters in Laval, Quebec, Canada, specializes in therapeutic fields such as neurology, dermatology, gastroenterology, and eye health. Bausch Health provides remedies for traveler's diarrhea, including oral rehydration solutions, probiotics, and antibiotics. The company's products help travelers prevent and manage diarrhea and are available for both prescription and over-the-counter markets. With operations in more than 100 nations, Bausch Health uses its global reach to treat gastrointestinal conditions like traveler's diarrhea.
Valvena SE
Valneva SE is a French biotech company specializing in vaccines for infectious diseases, established in 2013 through a merger between Vivalis SA and Intercell AG. Headquartered in Saint-Herblain, France, Valneva focuses on developing prophylactic vaccines with a current emphasis on diseases like Lyme disease, chikungunya, and COVID-19.
Other key players in the market include COSMO PHARMACEUTICALS, Immuron, Procter & Gamble, Norgine, and Perrigo.
Key Questions Answered in the Traveler’s Diarrhea Market Report
Traveler’s Diarrhea Market Overview
Traveler's diarrhea is a common gastrointestinal illness that often affects people who visit places with different standards of sanitation and food safety. Consuming contaminated food or water that contains bacteria, parasites (like E. coli), and viruses is the main cause of it. Frequent loose stools, abdominal cramps, nausea, and fever are common symptoms. The illness appears within a week of departure, but it can occur at any time during or after the trip. Most cases are mild and resolve on their own in 2-3 days, but severe cases may require professional medical attention. High-risk areas include countries and parts of the Middle East, Africa, Asia, and Latin America.
In unfamiliar surroundings, travellers frequently encounter pathogens that their immune systems have never encountered before. Visitors are more prone to infections than locals, who may have developed immunity over time. This is particularly true in areas where foodborne or waterborne pathogens, such as Rotavirus or Shigella, are more common but less well-known to tourists from developed countries.
Since dehydration is the main issue, oral rehydration fluids and solutions are essential for management. Examples of preventive measures include avoiding harmful foods and beverages, washing your hands frequently, and using prophylactic drugs or vaccines in specific circumstances. Moreover, travellers frequently believe that bottled water is safe, but in certain countries, tainted water may be sold because of illegal or poorly controlled bottling methods. In some places, tap water may also contain bacteria that cause diarrhea. Reliable access to safe drinking water is a crucial challenge because even seemingly clean water can contain pathogens if local treatment facilities are insufficient.
Traveler’s Diarrhea Market Growth Drivers
Growing Preference for Over the Counter (OTC) Medications to Drive Market Growth
Many tourists would rather use over-the-counter drugs like oral rehydration salts or loperamide (Imodium) to treat their own symptoms. The market for over-the-counter diarrhea remedies has grown because of this trend toward practical, easily accessible solutions. Pharma manufacturing companies are taking good advantage of this by providing products that are easy to use and come in portable, travel-friendly packaging. Hence, propelling the treatment options.
Traveler’s Diarrhea Market Trends
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:
Rising Antimicrobial Resistance to Affect the Market Landscape Significantly
Antimicrobial resistance brought on by the overuse and abuse of antibiotics in some regions of the world has made it more difficult to treat common bacteria. Infections brought on by resistant bacteria may cause travelers to have more severe or protracted symptoms, necessitating more intensive or complex medical treatments. Because of this, traveler's diarrhea is a bigger health risk in areas where resistance is high. For instance, in 2018, Procter & Gamble's new Liquicaps for Pepto Bismol was launched. This product was released as a practical way to treat diarrhea that was perfect for tourists. In contrast to conventional Pepto Bismol, the Liquicaps combat the bacteria that cause diarrhea in addition to treating its symptoms. This launch reflects a growing focus on portable, fast-acting treatments by offering consumers an easy-to-carry solution for digestive issues.
Development of Vaccines and Advances in Probiotic Treatments to Augment Traveler’s Diarrhea Market Demand
Emerging drivers include the creation and marketing of vaccines intended to stop the bacterial causes of traveler's diarrhea, such as those that target E. coli. The market is anticipated to be greatly impacted by these vaccines as they become approved and awareness increases, especially among high-risk travelers. The market is expanding due to the growing popularity of probiotics, which support gut health and may prevent or lessen diarrhea. Probiotics are increasingly being used by travelers as a preventative measure and as a component of a treatment plan, especially as the importance of gut microbiota is getting widely recognized. For Instance, FDA approved Aemcolo, a product of Cosmo Technologies, as a treatment for traveler's diarrhea. In clinical trials, Aemcolo demonstrated efficacy in symptom reduction, providing travelers with relief from E. coli-caused non-complicated diarrhea.
Traveler’s Diarrhea Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Causative Agents:
- Bacteria
- Viruses
- Protozoa
- Antibiotics
- Azithromycin
- Quinolones
- Others
- Anti-Diarrheal Agents
- Vaccines/Prophylactics
- Others
- Adults
- Children
- Hospitals
- Ambulatory Surgical Centres
- Clinics
- Others
- United States
- EU-4 and United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
The Virus Segment Holds a Significant Market Share
The market segmentation by causative agents is divided into bacteria, viruses, and protozoa. Traveler's diarrhea is mainly caused by viruses, especially in places with inadequate sanitation. Norovirus and rotavirus are the most prevalent viral pathogens, and they are transmitted by contaminated food, water, or contact with infected surfaces. The virus inflames the gastrointestinal (GI) tract, resulting in symptoms such as cramps in the abdomen, vomiting, and occasional fever. In comparison to bacterial causes, the viral diarrhea usually resolves on its own within two to three days. Dehydration can happen fast, particularly in susceptible groups like the elderly or children. Since antibiotics are ineffective against viruses, treatment focuses on rehydration and symptom management. Good hygiene and vaccinations (such as the rotavirus vaccine) are effective preventive measures.
Traveler’s Diarrhea Market Analysis by Region
Regionally, Asia Pacific is expected to dominate the market during the forecast period. This can primarily be attributed to rising international travelling and increasing contamination of food and water primarily due to unsanitary living standards and pollution in the region. India and other Asian countries dominated the market in Asia Pacific in 2021 owing to factors such as a high patient pool for major chronic diseases. Additionally, over the course of the forecast period, the presence of major players, early adoption of technology, rising focus on natural and herbal remedies and an increase in research and increasing easy access to travel health clinics are expected to help the regional growth of the market.
Leading Players in the Traveler’s Diarrhea Market
The key features of the market report comprise the patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Bausch Health Company
A multinational pharmaceutical corporation, Bausch Health Company creates, produces, and sells a variety of medical supplies. The company, which was founded in 1959 and has its headquarters in Laval, Quebec, Canada, specializes in therapeutic fields such as neurology, dermatology, gastroenterology, and eye health. Bausch Health provides remedies for traveler's diarrhea, including oral rehydration solutions, probiotics, and antibiotics. The company's products help travelers prevent and manage diarrhea and are available for both prescription and over-the-counter markets. With operations in more than 100 nations, Bausch Health uses its global reach to treat gastrointestinal conditions like traveler's diarrhea.
Valvena SE
Valneva SE is a French biotech company specializing in vaccines for infectious diseases, established in 2013 through a merger between Vivalis SA and Intercell AG. Headquartered in Saint-Herblain, France, Valneva focuses on developing prophylactic vaccines with a current emphasis on diseases like Lyme disease, chikungunya, and COVID-19.
Other key players in the market include COSMO PHARMACEUTICALS, Immuron, Procter & Gamble, Norgine, and Perrigo.
Key Questions Answered in the Traveler’s Diarrhea Market Report
- What was the Traveler’s Diarrhea market value in 2024?
- What is the Traveler’s Diarrhea market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is the market breakup based on causative agents?
- What is market segmentation based on drug type?
- What is the market breakup based on age?
- Who are the major end users in the market?
- What are the major factors aiding the Traveler’s diarrhea market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How do the prevalence and incidence of chronic diseases affect the market landscape?
- What are the major Traveler’s diarrhea market trends?
- How does the rise in the geriatric population impact the market size?
- Which product type will dominate the market share?
- Which application is expected to have a high market value in the coming years?
- Which end user is projected to contribute to the highest market growth?
- Who are the key players involved in the Traveler’s diarrhea market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Traveler’s Diarrhea Market Overview – 8 Major Markets
- 3.1 Traveler’s Diarrhea Market Historical Value 2018-2024
- 3.2 Traveler’s Diarrhea Market Forecast Value 2025-2034
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Traveler’s Diarrhea Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Traveler’s Diarrhea Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview 2018-2034
- 7.2 Prevalence, by Country
- 7.2.1 United States
- 7.2.2 United Kingdom
- 7.2.3 EU4
- 7.2.4 India
- 7.2.5 Japan
- 7.3 Diagnosed Cases, by Country
- 7.3.1 United States
- 7.3.2 United Kingdom
- 7.3.3 EU4
- 7.3.4 India
- 7.3.5 Japan
- 7.4 Treatment Seeking Rate, by Country
- 7.4.1 United States
- 7.4.2 United Kingdom
- 7.4.3 EU4
- 7.4.4 India
- 7.4.5 Japan
- 8 Traveler’s Diarrhea Market Landscape – 8 Major Markets
- 8.1 Traveler’s Diarrhea Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Traveler’s Diarrhea Market: Product Landscape
- 8.2.1 Analysis by Drug Type
- 8.2.2 Analysis by Age
- 9 Traveler’s Diarrhea Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Traveler’s Diarrhea Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Traveler’s Diarrhea Market Segmentation 218-2034 - 8 Major Markets
- 12.1 Traveler’s Diarrhea Market 2018-2034 by Causative Agents
- 12.1.1 Market Overview
- 12.1.2 Bacteria
- 12.1.3 Viruses
- 12.1.4 Protozoa
- 12.2 Traveler’s Diarrhea Market 2018-2034 by Drug Type
- 12.2.1 Market Overview
- 12.2.2 Antibiotics
- 12.2.2.1 Azithromycin
- 12.2.2.2 Quinolones
- 12.2.2.3 Others
- 12.2.3 Anti-Diarrheal Agents
- 12.2.4 Vaccines/Prophylactics
- 12.2.5 Others
- 12.3 Traveler’s Diarrhea Market 2018-2034 by Age
- 12.3.1 Market Overview
- 12.3.2 Adults
- 12.3.3 Children
- 12.4 Traveler’s Diarrhea Market 2018-2034 by End User
- 12.4.1 Market Overview
- 12.4.2 Hospitals
- 12.4.3 Ambulatory Surgical Centers
- 12.4.4 Clinics
- 12.4.5 Others
- 12.5 Traveler’s Diarrhea Market 2018-2034 by Region
- 12.5.1 Market Overview
- 12.5.2 United States
- 12.5.3 EU-4 and the United Kingdom
- 12.5.3.1 Germany
- 12.5.3.2 France
- 12.5.3.3 Italy
- 12.5.3.4 Spain
- 12.5.3.5 United Kingdom
- 12.5.4 Japan
- 12.5.5 India
- 13 United States Traveler’s Diarrhea Market 218-2034
- 13.1 United States Traveler’s Diarrhea Market 2018-2034 by Causative Agents
- 13.1.1 Market Overview
- 13.1.2 Bacteria
- 13.1.3 Viruses
- 13.1.4 Protozoa
- 13.2 United States Traveler’s Diarrhea Market 2018-2034 by Drug Type
- 13.2.1 Market Overview
- 13.2.2 Antibiotics
- 13.2.2.1 Azithromycin
- 13.2.2.2 Quinolones
- 13.2.2.3 Others
- 13.2.3 Anti-Diarrheal Agents
- 13.2.4 Vaccines/Prophylactics
- 13.2.5 Others
- 13.3 United States Traveler’s Diarrhea Market 2018-2034 by Age
- 13.3.1 Market Overview
- 13.3.2 Adults
- 13.3.3 Children
- 13.4 United States Traveler’s Diarrhea Market 2018-2034 by End User
- 13.4.1 Market Overview
- 13.4.2 Hospitals
- 13.4.3 Ambulatory Surgical Centers
- 13.4.4 Clinics
- 13.4.5 Others
- 14 EU-4 and United Kingdom Traveler’s Diarrhea Market 218-2034
- 14.1 EU-4 and United Kingdom Traveler’s Diarrhea Market 2018-2034 by Causative Agents
- 14.1.1 Market Overview
- 14.1.2 Bacteria
- 14.1.3 Viruses
- 14.1.4 Protozoa
- 14.2 EU-4 and United Kingdom Traveler’s Diarrhea Market 2018-2034 by Drug Type
- 14.2.1 Market Overview
- 14.2.2 Antibiotics
- 14.2.2.1 Azithromycin
- 14.2.2.2 Quinolones
- 14.2.2.3 Others
- 14.2.3 Anti-Diarrheal Agents
- 14.2.4 Vaccines/Prophylactics
- 14.2.5 Others
- 14.3 EU-4 and United Kingdom Traveler’s Diarrhea Market 2018-2034 by Age
- 14.3.1 Market Overview
- 14.3.2 Adults
- 14.3.3 Children
- 14.4 EU-4 and United Kingdom Traveler’s Diarrhea Market 2018-2034 by End User
- 14.4.1 Market Overview
- 14.4.2 Hospitals
- 14.4.3 Ambulatory Surgical Centers
- 14.4.4 Clinics
- 14.4.5 Others
- 15 Japan Traveler’s Diarrhea Market 218-2034
- 15.1 Japan Traveler’s Diarrhea Market 2018-2034 by Causative Agents
- 15.1.1 Market Overview
- 15.1.2 Bacteria
- 15.1.3 Viruses
- 15.1.4 Protozoa
- 15.2 Japan Traveler’s Diarrhea Market 2018-2034 by Drug Type
- 15.2.1 Market Overview
- 15.2.2 Antibiotics
- 15.2.2.1 Azithromycin
- 15.2.2.2 Quinolones
- 15.2.2.3 Others
- 15.2.3 Anti-Diarrheal Agents
- 15.2.4 Vaccines/Prophylactics
- 15.2.5 Others
- 15.3 Japan Traveler’s Diarrhea Market 2018-2034 by Age
- 15.3.1 Market Overview
- 15.3.2 Adults
- 15.3.3 Children
- 15.4 Japan Traveler’s Diarrhea Market 2018-2034 by End User
- 15.4.1 Market Overview
- 15.4.2 Hospitals
- 15.4.3 Ambulatory Surgical Centers
- 15.4.4 Clinics
- 15.4.5 Others
- 16 India Traveler’s Diarrhea Market 218-2034
- 16.1 India Traveler’s Diarrhea Market 2018-2034 by Causative Agents
- 16.1.1 Market Overview
- 16.1.2 Bacteria
- 16.1.3 Viruses
- 16.1.4 Protozoa
- 16.2 India Traveler’s Diarrhea Market 2018-2034 by Drug Type
- 16.2.1 Market Overview
- 16.2.2 Antibiotics
- 16.2.2.1 Azithromycin
- 16.2.2.2 Quinolones
- 16.2.2.3 Others
- 16.2.3 Anti-Diarrheal Agents
- 16.2.4 Vaccines/Prophylactics
- 16.2.5 Others
- 16.3 India Traveler’s Diarrhea Market 2018-2034 by Age
- 16.3.1 Market Overview
- 16.3.2 Adults
- 16.3.3 Children
- 16.4 India Traveler’s Diarrhea Market 2018-2034 by End User
- 16.4.1 Market Overview
- 16.4.2 Hospitals
- 16.4.3 Ambulatory Surgical Centers
- 16.4.4 Clinics
- 16.4.5 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 Japan PMDA
- 17.5 India CDSCO
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 19 Clinical Trials Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grants Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Application
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by NIH Departments
- 20.7 Analysis by Recipient Organization
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Drug Class of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Drug Class of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share Analysis, By Region (Top 5 Companies)
- 23.2 Bausch Health Company
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Company News and Developments
- 23.2.5 Certifications
- 23.3 COSMO PHARMACEUTICALS
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Company News and Developments
- 23.3.5 Certifications
- 23.4 Immuron
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Company News and Developments
- 23.4.5 Certifications
- 23.5 Valvena SE
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Company News and Developments
- 23.5.5 Certifications
- 23.6 Proctor & Gamble
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Company News and Developments
- 23.6.5 Certifications
- 23.7 Norgine
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Company News and Developments
- 23.7.5 Certifications
- 23.8 Perrigo
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Company News and Developments
- 23.8.5 Certifications
- 24 Traveler’s Diarrhea Market - Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
